目的:评估“三亚共识”对原发性肝癌肝移植治疗的临床价值。方法:回顾性分析2003年4月至2006年1月间第二军医大学东方肝胆外科医院收治的75例因原发性肝癌接受原位肝移植病人，对其与各种肝移植标准的匹配情况进行研究。结果:全部75例病人术后1、2、3年的总体存活率及无瘤存活率分别为85%、74%、67%和80%、74%、66%。“三亚共识”组术后1、2、3年总体存活率及无瘤存活率分别为92%、88%、74%、和92%、88%、72%。“三亚共识”与其他三种标准相比术后总体存活率及无瘤存活率差异均无统计学意义。结论:“三亚共识”是一种有效的筛选标准。“三亚共识”与UCSF标准可能更适用于目前中国的肝癌肝移植筛选。

Objective:To evaluate the clinical value of the Sanya Criteria in the treatment of liver transplantation for hepatocellular carcinoma. Methods:Seventyfive patients who had underwent OLT for hepatocellular carcinoma from April 2003 to January 2006 in the Eastern Hepatobiliary Srugery Hospital were retrospectively analyzed.The matching degree of the Sanya Criteria and other criteria for liver transplantation was studied. Results:The 1,2,3year overall survival rates of the total 75 patients after operation were 85%,74% and 67%,respectively and the recurrencefree survival rates were 80%,74% and 66%,respectively.The data in the Sanya Group were 92%,88%,74% and 92%,88%,72%,respectively.There was no significant difference between Sanya Criteria and the other criteria with regard to the postOLT survival rates. Conclusion:The SanYa Criteria is an efficient screening standard. The SanYa Criteria and the UCSF Criteria may be more applicable to the screening for liver transplantation in patients suffering from hepatocellular carcinoma